Press ReleaseSource: Brower Piven, A Professional Corporation

Brower Piven Announces Expanded Class Period and Encourages Investors Who Have Losses in Excess of $100,000 From Investment in The Spectranetics Corporation to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the November 24, 2008 Lead Plaintiff Deadline
Monday November 10, 2008 11:45 am ET

BALTIMORE, MD--(MARKET WIRE)--Nov 10, 2008 -- Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Colorado on behalf of purchasers of the publicly traded securities of The Spectranetics Corporation ("Spectranetics" or the "Company") (NasdaqGM:SPNC - News) during the period between April 26, 2005 and September 3, 2008, inclusive (the "Class Period").

The complaint charges Spectranetics and certain of its officers and directors with violations under the Securities Exchange Act of 1934. No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff no later than November 24, 2008 and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the Company during the Class Period. You may contact Brower Piven (through hoffman@browerpiven.com or 410/332-0030) to answer any questions you may have in that regard.

The complaint alleges that during the Class Period, defendants failed to disclose that the Company was improperly promoting its own products and the products of third parties, was improperly compensating personnel and was receiving parts from an international source in violation of customs laws. The complaint further alleges that on September 4, 2008, the Company announced that it had been served by the Food and Drug Administration and U.S. Immigration and Customs Enforcement with a search warrant issued by the United States District Court, District of Colorado requesting information and correspondence relating to the promotion, use, testing, marketing and sales of certain of the Company's products, among other things. The complaint goes on to allege that as a result of this disclosure, the value of the Company's shares declined substantially.

If you have suffered a net loss for all transactions in The Spectranetics Corporation securities during the Class Period (including shares or possibly calls purchased during, but retained after, the Class Period or possibly put options sold but not covered until after the Class Period), you may obtain additional information about this lawsuit and your ability to become a lead plaintiff by contacting Brower Piven at www.browerpiven.com, by email at hoffman@browerpiven.com, by calling 410-332-0030, or at Brower Piven, A Professional Corporation, The World Trade Center-Baltimore, 401 East Pratt Street, Suite 2525, Baltimore, Maryland 21202. Attorneys at Brower Piven have combined experience litigating securities and class action cases of over 40 years. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.


Contact:
     CONTACT:
     Charles J. Piven
     Brower Piven, A Professional Corporation
     Baltimore, Maryland
     410/332-0030
     Email Contact
      

Source: Brower Piven, A Professional Corporation


Mail to Friend Email Story
Alerts Set News Alert
Printer
Version  Print Story 


Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Copyright © 2009 Marketwire. All rights reserved. All the news releases provided by Marketwire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.